Brentview Investment Management LLC Increases Stock Holdings in Johnson & Johnson $JNJ

Brentview Investment Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,266 shares of the company’s stock after purchasing an additional 5,337 shares during the quarter. Johnson & Johnson comprises about 2.2% of Brentview Investment Management LLC’s holdings, making the stock its 22nd biggest holding. Brentview Investment Management LLC’s holdings in Johnson & Johnson were worth $4,870,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the period. Geode Capital Management LLC boosted its holdings in Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the period. Norges Bank acquired a new position in Johnson & Johnson during the 2nd quarter worth $4,877,174,000. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after purchasing an additional 835,146 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Johnson & Johnson by 2.8% during the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock worth $3,606,431,000 after purchasing an additional 532,790 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on JNJ shares. Loop Capital set a $220.00 price objective on Johnson & Johnson in a research note on Tuesday, January 27th. Leerink Partners raised their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Finally, Morgan Stanley set a $262.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $234.87.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Stock Performance

Shares of JNJ opened at $243.75 on Wednesday. The company has a market capitalization of $587.41 billion, a price-to-earnings ratio of 22.06, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock has a 50 day moving average price of $229.80 and a 200 day moving average price of $205.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.